AngElle Bioengineering ApS: Financial statements 2023
CVR: 43155881
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
AngElle Bioengineering ApS (CVR 43155881) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -1,168 and a net result of DKK -1,168. Equity in the 2023 report amounted to DKK 102,560. The solvency ratio was 100%.
- Revenue
- DKK 0
- Gross Profit
- DKK -1,168
- Profit/Loss
- DKK -1,168
- Equity
- DKK 102,560
- Total Assets
- DKK 102,560
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
AngElle Bioengineering ApS has published its interim report for the period March 25, 2022 – December 31, 2022.
About AngElle Bioengineering ApS
AngElle Bioengineering ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2022. The company is registered under the industry Anden teknisk rådgivning. The management consists of Irini Angelidaki. The company is owned by Irini Angelidaki. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -58,328 compared with DKK 38,363 the year before. Equity in the 2025 report amounted to DKK 82,579.